AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 5, line 1 as follows:

R_1 can further be a 2- or 4-pyrimidinyl heterocycle, where the 2-pyrimidinyl ring can be mono- or polysubstituted by ~~the~~ methyl~~; group, furthermore are [sic] the~~ a 2-, 3-, ~~and~~ 4- ~~and~~ or 8-quinolyl structure that may be substituted by (C_1-C_6)-alkyl, halogen, ~~the~~ nitro~~-group~~, ~~the~~ amino ~~group and~~ or ~~the~~ (C_1-C_6)-alkylamino ~~radical, are [sic]~~ or : a 2-, 3-, ~~and [sic]~~or 4-quinolylmethyl group, where the ring carbons of the pyridylmethyl radical of the quinolyl group and of the quinolylmethyl radical ~~can~~ may be substituted by (C_1-C_6)-alkyl, (C_1-C_6)-alkoxy, nitro, amino ~~and~~ or (C_1-C_6)-alkoxycarbonylamino.

Please insert the following paragraph on page 9, line 20:

FIG. 1 shows the cytotoxic action of compound D-24851 against MDR murine leukemic subline L1210/VCR.

FIG. 2 demonstrates the action of compound D-24851 on a multidrug-resistant tumor.

FIG. 3 shows the influence on the multi-drug-resistant murine leukemia L1210 (dose 10% of the LD.sub.50).

FIG. 4 compares the effect compound D-24851 on human leukemia cells with the effect of other neoplastic agents on the same leukemia cells.

FIG. 5 shows the inhibition of migration of MO4 cells by compound D-24851.

FIG. 6 shows a comparison of neurotoxicity induced by compound D-24851 versus other neoplastic agents.

FIG. 7 shows the influence of compound D-24851 on nerve conduction velocity in rat.

FIG. 8 compares angiogenesis in human endothelial cells in compound D-24851-treated cells versus DMSO (44 hours after induction of angiogenesis).

FIG. 9 compares angiogenesis in human endothelial cells in compound D-24851-treated cells versus DMSO (22 hours after induction of angiogenesis).